Shots:

• The drug failed to meet the primary endpoint of thyroid cancer lead to its failure as well as removal from phase 3- double blind involved in high risk DTC
• The licensor AstraZeneca refused to pay royalties to the license Array pharma for the drug
• AstraZeneca to pay $192million according to licensing deal to Array Pharm

 Ref: Array Biopharma | Image: AstraZeneca